Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says
Lucid Diagnostics confirmed its first LBM win with Concert, opens up 10M covered lives. Analyst maintains Buy rating and $2.50 PT.
Lucid Diagnostics just got its first big customer (Concert) and now 10 million people have insurance that might cover its test. This is a good step forward, and some experts think Medicare might approve it soon too.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.